Rubio-San-Simón, A.
Verdú-Amorós, J.
Hladun, R.
Juan-Ribelles, A.
Molero, M.
Guerra-García, P.
Pérez-Martínez, A.
Castañeda, A.
Cañete, A.
de Rojas, T.
Moreno, L.
Bautista, F. http://orcid.org/0000-0002-0421-8862
Article History
Received: 5 May 2020
Accepted: 12 May 2020
First Online: 29 May 2020
Compliance with ethical standards
:
: F Bautista had a consultant or advisory role for Bayer, Amgen, Sanofi, and EusaPharma, received honoraria for speaking at symposia from Amgen and Jazz Pharmaceuticals, and support for attending symposia from Takeda, EusaPharma, Shire, and Jazz Pharmaceuticals. L Moreno had a consulting or advisory role for Novartis, AstraZeneca, Roche Genentech, Bayer, Amgen, and MundiPharma. He received honoraria from Celgene and Novartis for educational events and travel expenses from MundiPharma, Celgene, Amgen. L Moreno is a member of the Executive Committee of SIOPEN, non-profit organization that receives royalties for the sales of dinutuximab beta. A. Cañete had a consulting or advisory role for Eusa Pharma and Bayer. She received honoraria from Usa Pharma for educational events and travel expenses. A. Canete is a member of the Executive Committee of SIOPEN, non-profit organization that receives royalties for the sales of dinutuximab beta. The rest of the authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the participant institutions research committes and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individuals participating in clinical trials.
Free to read: This content has been made available to all.